Goldman Sachs
LJPC

Goldman Sachs’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Goldman Sachs’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-13,718
Closed -$59K – 6978
2022
Q1 		$59K Sell
13,718
-21,859
-61% -$95.3K ﹤0.01% 6235
2021
Q4 		$165K Sell
35,577
-8,545
-19% -$35.6K ﹤0.01% 5975
2021
Q3 		$176K Sell
44,122
-102,403
-70% -$406K ﹤0.01% 5766
2021
Q2 		$627K Buy
146,525
+8,875
+6% +$38K ﹤0.01% 5088
2021
Q1 		$583K Buy
137,650
+13,704
+11% +$75.5K ﹤0.01% 5008
2020
Q4 		$481K Sell
123,946
-5,736
-4% -$24.5K ﹤0.01% 4631
2020
Q3 		$522K Buy
129,682
+94,129
+265% +$390K ﹤0.01% 4462
2020
Q2 		$151K Buy
35,553
+14,358
+68% +$87.4K ﹤0.01% 4890
2020
Q1 		$89K Sell
21,195
-181,364
-90% -$1.15M ﹤0.01% 4961
2019
Q4 		$796K Buy
202,559
+176,706
+684% +$1.04M ﹤0.01% 4255
2019
Q3 		$228K Buy
25,853
+6,388
+33% +$60.4K ﹤0.01% 4778
2019
Q2 		$180K Sell
19,465
-24,540
-56% -$185K ﹤0.01% 4829
2019
Q1 		$283K Sell
44,005
-22,015
-33% -$143K ﹤0.01% 4659
2018
Q4 		$623K Buy
66,020
+8,416
+15% +$127K ﹤0.01% 4242
2018
Q3 		$1.16M Buy
57,604
+18,820
+49% +$492K ﹤0.01% 3950
2018
Q2 		$1.13M Buy
38,784
+29,356
+311% +$906K ﹤0.01% 3998
2018
Q1 		$281K Sell
9,428
-18,246
-66% -$588K ﹤0.01% 4818
2017
Q4 		$891K Buy
27,674
+5,147
+23% +$168K ﹤0.01% 4412
2017
Q3 		$783K Buy
22,527
+7,226
+47% +$232K ﹤0.01% 4786
2017
Q2 		$456K Sell
15,301
-9,181
-38% -$263K ﹤0.01% 5164
2017
Q1 		$731K Buy
+24,482
New +$625K ﹤0.01% 4674
2016
Q2 		– Sell
-15,743
Closed -$329K – 7594
2016
Q1 		$329K Buy
15,743
+4,885
+45% +$87.1K ﹤0.01% 5180
2015
Q4 		$293K Buy
10,858
+3,981
+58% +$109K ﹤0.01% 5375
2015
Q3 		$191K Buy
+6,877
New +$217K ﹤0.01% 6051
2015
Q2 		– Sell
-16,052
Closed -$294K – 7729
2015
Q1 		$294K Buy
+16,052
New +$325K ﹤0.01% 5670

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KT
Kevin Tang $783 AUM 75.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Goldman Sachs's LJPC Position: Q2 2022 in Review

Goldman Sachs sold out of La Jolla Pharmaceutical Company (LJPC) in Q2 2022, closing a stake of 13,718 shares — an estimated $59K sold.

Goldman Sachs first reported a position in LJPC in Q1 2015 and held it in 25 quarters. The position peaked at $1.16M in Q3 2018. 41 funds tracked by Wall St. Rank hold LJPC as of Q2 2022.

  • Goldman Sachs reported no remaining La Jolla Pharmaceutical Company position as of Q2 2022 after selling out during the quarter.
  • Goldman Sachs sold 13,718 La Jolla Pharmaceutical Company shares in Q2 2022, an estimated $59K.
  • Goldman Sachs first reported a position in La Jolla Pharmaceutical Company in Q1 2015 and held it in 25 quarters.
  • Goldman Sachs's La Jolla Pharmaceutical Company position peaked at $1.16M in Q3 2018.
  • 41 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q2 2022.

Based on Goldman Sachs's 13F filing for Q2 2022, filed 15 Aug 2022.